Daniel Montoya, Ph.D.

At FSU since 2005

Dr. Montoya earned his Ph. D, degree from the National University of Cordoba in Argentina in 1998. This degree was the result of several years of effort at the Medical Research Institute Mercedes and Martin Ferreyra, studying the effects of different hormonal treatments on hippocampal plasticity. On the same week of finishing his doctorate, he took a flight to North Carolina were he spend the next three years at Duke University, as a postdoctoral research assistant, studying the effects of cholinergic prenatal treatment on hippocampal plasticity at a behavioral and neurophysiological level. After a short period of time in Wake Forest University, he moved to Bowling Green State University, in Ohio, where he continued his studies on the septo-hippocampal system and the effects of GABAergic and cholinergic lesions.
 
Dr. Montoya is an Assistant Professor in the Department of Psychology at Fayetteville State University. He is a member of the Society for Neuroscience and Behavioral Neuroscience is his main area of expertise. His teaching interests are in the area of biological psychology, psychopharmacology and experimental psychology. He also has a long standing interest in the “hard problem” of consciousness and its philosophical implications. His current and future research priorities are the development of an Experimental Psychology lab and the translation of certain neurophysiological findings in animals to the human studies of EEG and reaction times.
 

Recent publications:

 
Levin, E. D., Rezvani, A. H., Montoya, D., et. al. (2003).  Adolescent-onset nicotine self-administration modeled in female rats. Psychopharmacology, 69(2), 141-149.
 
Montoya, D. (2002). Prenatal choline supplementation protects against postnatal neurotoxicity. The Journal of Neuroscience, 22(1), RC195.
 
Grobin, A. C., Matthews, D. B., Montoya, D., Wilson, W. A., Morrow, A. L., & Swartzwelder, H. S. (2001). Age-related differences in neurosteroid potentiation of muscimol-stimulated 36Cl(-) flux following chronic ethanol treatment. Neuroscience, 105(3), 547-552.